Treatment Resistance Following Anti-cancer Therapies

Inclusion Criteria: * Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors treated as follows: * Non small cell lung carcinoma (NSCLC) monotherapy: Disease progression (PD) on 1st line monotherapy anti PD-1/ L1. * NSCLC combination: PD on 1st line anti PD-1/ L1 plus standard doublet platinum containing regimen; or PD on 1st-line anti-PD-1/-L1 plus standard doublet platinum-containing regimen followed by continuation of single agent anti-PD-1/-L1). * Renal cell carcinoma (RCC) with clear cell component: PD on 2nd line monotherapy anti PD-1/ L1; or PD on 1st line combination of doublet anti-PD-1/ L1 with anti-CTLA-4; or PD on 1st-line combination of avelumab with axitinib or pembrolizumab with axitinib. * HR+ HER2 adenocarcinoma of the breast: PD on 1st line combination of doublet palbociclib with hormonal therapy. * Castrate resistant adenocarcinoma of the prostate: PD on enzalutamide monotherapy. * Castrate resistant adenocarcinoma of the prostate: PD on abiraterone in combination with prednisone. * germline mutated BRCA (gBRCAm), HER2- breast cancer: PD on a PARP inhibitor monotherapy in patients previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. * Radiographic evidence of PD, including the target lesion being subjected to biopsy for the study, on the most recent regimen that requires a change in anti-cancer treatment. Exclusion Criteria: * Tumor biopsy taken from a bone or an irradiated target lesion. * Discontinuation of current or most recent anti cancer therapy due to toxicity and not progressive disease. * Initiation of new anti-cancer therapy after disease progression prior to planned biopsy.